DATABASE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

ORMP — Oramed Pharmaceuticals Inc.

ORMP (Oramed Pharmaceuticals Inc.) stock: $4.75, $197.4M market cap, $16.1M cash, $181.3M EV, $197.6M fully diluted market cap. Next expected readout: Apr-27. Lead program: ORMD-0801 8 mg (Type 2 Diabetes Mellitus), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price
$4.75
Market cap
$197.4M
Cash
$16.1M
Enterprise value
$181.3M

Balance sheet

Cash$16.1M
Debt$0.0M
Net cash$16.1M
Enterprise value$181.3M
Basic shares41.3M shares
Fully diluted shares41.6M shares
Fully diluted market cap$197.6M
Cash per share$0.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading ORMP daily closes…

Loading price history…

Upcoming catalysts

ExpectedDrugPhaseIndicationMgmt guide
Jun 6 - Jul 18ORMD-0801 8 mgPhase 3Type 2 Diabetes Mellitus

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.
Subscribe to Compounding Ego